These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 183789)

  • 41. [Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)].
    Schwartzkopff W; Zschiedrich M
    Med Klin; 1978 Feb; 73(7):231-9. PubMed ID: 203832
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of a new niacin derivative (nicotinic hexaester of D-glucitol) on type IIA, IIB and IV hyperlipoproteinemia in man.
    Avogaro P; Bittolo-Bon G; Pais M; Taroni GC
    Pharmacol Res Commun; 1977 Jun; 9(6):599-606. PubMed ID: 197548
    [No Abstract]   [Full Text] [Related]  

  • 43. [Treatment of essential hyperlipidemia with procetofene. Apropos of 100 cases].
    Fromantin M; Gautier D; Bon R
    Sem Hop Ther; 1977; 53(5-6):311-6. PubMed ID: 897691
    [No Abstract]   [Full Text] [Related]  

  • 44. Combined para-aminosalicylic acid and dietary therapy in long-term control of hypercholesterolemia and hypertriglyceridemia (Types IIa and IIb hyperlipoproteinemia).
    Kuo PT; Fan WC; Kostis JB; Hayase K
    Circulation; 1976 Feb; 53(2):338-41. PubMed ID: 173477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of CH 13.437 in different types of hyperlipidemia.
    Harvengt C
    Arch Int Pharmacodyn Ther; 1972 Apr; 196():Suppl 196:298+. PubMed ID: 4559547
    [No Abstract]   [Full Text] [Related]  

  • 46. [Study of hypolipemic effect of atheroid in ischemic heart disease associated with various types of hyperlipoproteinemia].
    Zakharov VN
    Sov Med; 1978 Jan; (1):147-8. PubMed ID: 76342
    [No Abstract]   [Full Text] [Related]  

  • 47. [Treatment of primary hyperlipoproteinemia type IIa and IIb with dextrothyroxine (author's transl)].
    Koschinsky T; Vogelberg KH; Gries FA
    Dtsch Med Wochenschr; 1974 Mar; 99(11):494-6. PubMed ID: 4365046
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of SU-13437 on serum lipids in hyperlipoproteinemic patients.
    Weiss P; Dujovne CA; Margolis S; Lasagna L; Bianchine JR
    Clin Pharmacol Ther; 1970; 11(1):90-6. PubMed ID: 4903694
    [No Abstract]   [Full Text] [Related]  

  • 49. [Type IIA hyperlipoproteinemia].
    Furs VA; Barashnev IuI; Ananenko AA; Pukhovskaia NV
    Pediatriia; 1977 Nov; (11):43-6. PubMed ID: 203893
    [No Abstract]   [Full Text] [Related]  

  • 50. Lipid-lowering effects of procetofene.
    Afschrift M; Mets T; Verdonk G
    Lancet; 1977 Aug; 2(8032):311. PubMed ID: 69930
    [No Abstract]   [Full Text] [Related]  

  • 51. Treatment of hypercholesterolaemia and hypertriglyceridaemia with magnesium.
    Petersen B; Christiansen C; Hansen PF
    Acta Med Scand; 1976; 200(1-2):59-61. PubMed ID: 785961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antilipidemic effect of nafenoic acid.
    Russo C; Mendlowitz M
    Clin Pharmacol Ther; 1971; 12(4):676-7. PubMed ID: 4936040
    [No Abstract]   [Full Text] [Related]  

  • 53. Type IIa hyperlipoproteinemia and the HLA system.
    Raffoux C; Pointel JP; Drouin P; Streiff F; Debry G; Sauvanet JP
    Tissue Antigens; 1978 Jan; 11(1):55-8. PubMed ID: 204075
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical pharmacology of DEAE-dextran for long-term administration (one year).
    Pupita F; Barone A
    Int J Clin Pharmacol Res; 1983; 3(4):287-93. PubMed ID: 6206004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of a major metabolite of the new hypolipidaemic agent, isopropyl 2-(4'(p-chlorobenzoyl) phenoxy)-2-methylpropionate (procetofene) in humans by gas chromatography-mass spectrometry.
    Elsom LF; Hawkins DR; Chasseaud LF
    J Chromatogr; 1976 Aug; 123(2):463-7. PubMed ID: 956317
    [No Abstract]   [Full Text] [Related]  

  • 56. Treatment of dyslipidemia: room for improvement?
    Crouse JR; Furberg CD
    Arterioscler Thromb Vasc Biol; 2000 Nov; 20(11):2333-5. PubMed ID: 11073834
    [No Abstract]   [Full Text] [Related]  

  • 57. Distribution of fenofibric acid in lipoprotein fractions of patients.
    Nobilis M; Kvetina J; Anzenbacher P; Vontor T; Svoboda D; Brátová M; Solichová D; Zadák Z; Bláha V; Vlcek J
    Eur J Drug Metab Pharmacokinet; 1998; 23(2):287-94. PubMed ID: 9725495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiviral activity of antilipidemic compounds on herpes simplex virus type 1.
    Mehl JK; Witiak DT; Hamparian VV; Hughes JH
    Antimicrob Agents Chemother; 1980 Aug; 18(2):269-75. PubMed ID: 6255860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
    Ferry N; Bernard N; Pozet N; Gardes E; Cuisinaud G; Labeeuw M; Zech PY; Sassard J
    Br J Clin Pharmacol; 1989 Dec; 28(6):675-81. PubMed ID: 2611089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antilipidemic drugs. Part 6: LF 178 in man. A preliminary note on a multicenter investigation bearing on 393 subjects with pure or mixed forms of hyperlipidemia.
    Wülfert B; Majoie B; de Ceaurriz A
    Arzneimittelforschung; 1976; 26(5):906-9. PubMed ID: 183789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.